These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35494073)

  • 1. Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker in Unresectable or Metastatic Esophageal Cancer Patients With Anti-PD-1 Therapy.
    Gao Y; Zhang Z; Li Y; Chen S; Lu J; Wu L; Ma Z; Hu Y; Zhang G
    Front Oncol; 2022; 12():834564. PubMed ID: 35494073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of esophageal cancer immune prognostic index in advanced esophageal squamous cell carcinoma patients with anti-programmed cell death-1 therapy.
    Lu J; Du L; Lei X; Zhang Z
    Cancer Med; 2023 May; 12(10):11334-11343. PubMed ID: 36951584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 4. Correlation Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Programmed Death-Ligand 1 Expression as Prognostic Markers in Non-Small Cell Lung Cancer.
    Pirlog CF; Cotan HT; Parosanu A; Orlov Slavu C; Popa AM; Iaciu C; Olaru M; Oprita AV; Nita I; Nitipir C
    Cureus; 2022 Jul; 14(7):e26843. PubMed ID: 35974841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer.
    Gou M; Qu T; Wang Z; Yan H; Si Y; Zhang Y; Dai G
    J Immunol Res; 2021; 2021():2549295. PubMed ID: 34993252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment Neutrophil-to-Lymphocyte Ratio: A Prognostic Biomarker of Survival in Patients With Epithelial Ovarian Cancer.
    John-Olabode SO; Okunade KS; Olorunfemi G; Soibi-Harry A; Rimi G; Osunwusi B; Okunowo A; Amaeshi L; Anorlu R
    Cureus; 2021 Jul; 13(7):e16429. PubMed ID: 34422466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in patients with advanced gastrointestinal stromal tumors treated with sunitinib after imatinib failure.
    Sobczuk P; Teterycz P; Lugowska I; Klimczak A; Bylina E; Czarnecka AM; Kosela-Paterczyk H; Osuch C; Streb J; Rutkowski P
    Oncol Lett; 2019 Sep; 18(3):3373-3380. PubMed ID: 31452817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy.
    Li L; Pi C; Yan X; Lu J; Yang X; Wang C; Li X; Zhang S; Zhang Z; Sun Y; Hu Y
    Front Oncol; 2021; 11():697865. PubMed ID: 34692478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen X; Meng F; Jiang R
    Front Oncol; 2021; 11():746976. PubMed ID: 34900692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis.
    Shao Y; Wu B; Jia W; Zhang Z; Chen Q; Wang D
    BMC Urol; 2020 Jul; 20(1):90. PubMed ID: 32631294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed death ligand 1 expression in esophageal cancer following definitive chemoradiotherapy: Prognostic significance and association with inflammatory biomarkers.
    Tang Y; Li G; Wu S; Tang L; Zhang N; Liu J; Zhang S; Yao L
    Oncol Lett; 2018 Apr; 15(4):4988-4996. PubMed ID: 29552135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
    Deng M; Ma X; Liang X; Zhu C; Wang M
    Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
    Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
    Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs).
    Li Y; Zhang Z; Hu Y; Yan X; Song Q; Wang G; Chen R; Jiao S; Wang J
    Front Oncol; 2020; 10():654. PubMed ID: 32656072
    [No Abstract]   [Full Text] [Related]  

  • 16. Pretreatment neutrophil-to-lymphocyte ratio is a predictive biomarker for EGFR TKI-treated patients with advanced EGFR-mutant Non-small cell lung cancer.
    Xu C; Yao X; Li T; Wang J; An B; Wang J; Sui X; Leung EL; Wu Q
    Transl Cancer Res; 2020 Apr; 9(4):2875-2883. PubMed ID: 35117644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) in locally advanced non-small cell lung cancer patients treated with thoracic radiation].
    Dong X; Zhou ZM; Bi N; Wang JB; Ran JT; Hui ZG; Liang J; Feng QF; Chen DF; Xiao ZF; Lyu JM; Wang XZ; Wang X; Zhang T; Deng L; Wang WQ; Wang LH
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):446-451. PubMed ID: 29936771
    [No Abstract]   [Full Text] [Related]  

  • 18. High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy.
    Bartlett EK; Flynn JR; Panageas KS; Ferraro RA; Sta Cruz JM; Postow MA; Coit DG; Ariyan CE
    Cancer; 2020 Jan; 126(1):76-85. PubMed ID: 31584709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated Neutrophil-to-Lymphocyte Ratio Is Associated With Poor Outcomes for Melanoma Patients Treated With PD-1 Inhibitor or Chemotherapy in a Chinese Population.
    Qi Y; Liao D; Mei D; Zhang Y; Liu Y
    Front Oncol; 2020; 10():1752. PubMed ID: 33042821
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic value of neutrophil to lymphocyte ratio in gastric cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
    Zhang S; Qiu C; Yu H; Xu Y; Xu X
    Front Oncol; 2023; 13():1070019. PubMed ID: 37143942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.